N Shudo
Overview
Explore the profile of N Shudo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sumizawa T, Chen Z, CHUMAN Y, Seto K, Furukawa T, Haraguchi M, et al.
Mol Pharmacol
. 1997 Mar;
51(3):399-405.
PMID: 9058594
Three agents, verapamil, cepharanthine, and 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl-5-(trans-4,6-dimethyl-1, 3,2-dioxaphosphorinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-3-py ridinecarboxylate P-oxide (PAK-104P), that reverse drug resistance in P-glycoprotein (P-Gp)-mediated multidrug-resistant cells were examined for their activity to reverse drug resistance in multidrug...
2.
Shudo N, Fujii R, Matsumoto T, Mizoguchi T, Seto K, Sakoda R, et al.
Jpn J Cancer Res
. 1992 Sep;
83(9):1011-7.
PMID: 1429198
A newly synthesized dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorina n-2-yl)-1- (2-morpholinoethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate (PAK-200), at 1 microM completely reversed the resistance to vincristine in vincristine-resistant P388 mouse leukemia cells (P388/VCR), in vitro. PAK-200 at...
3.
Niwa K, Yamada K, Furukawa T, Shudo N, Seto K, Matsumoto T, et al.
Cancer Res
. 1992 Jul;
52(13):3655-60.
PMID: 1617639
A newly synthesized dihydropyridine analogue, 2-[benzyl(phenyl)-amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorina n-2-yl)-1- (2-morpholinoethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate (PAK-200), at 5 microM inhibited the efflux of [3H]vincristine from KB-C2 cells and increased the accumulation of [3H]vincristine in KB-C2 cells...
4.
Harada H, Kawaharada N, Taguchi A, Ichimiya Y, Ueda M, Shudo N, et al.
Kyobu Geka
. 1991 Oct;
44(11):945-8.
PMID: 1942691
In a case with impending rupture of the thoracoabdominal aneurysm of a 78-year-old aged who was admitted to our hospital as chief complaints of dysphagia, sense of pressure in the...
5.
Ichikawa M, Yoshimura A, Sumizawa T, Shudo N, Kuwazuru Y, Furukawa T, et al.
J Biol Chem
. 1991 Jan;
266(2):903-8.
PMID: 1670776
P-glycoprotein (P-gp) is thought to mediate the transport of anti-cancer drugs and to be responsible for the multidrug-resistant (MDR) phenotype in tumor cells. However, the function of P-gp in normal...
6.
Shudo N, Mizoguchi T, Kiyosue T, Arita M, Yoshimura A, Seto K, et al.
Cancer Res
. 1990 May;
50(10):3055-61.
PMID: 1970752
Four pyridine analogues and their dihydropyridine counterparts were examined for their ability to reverse drug resistance in a multidrug-resistant human carcinoma cell line, KB-C2. Two pyridine analogues were more able...
7.
Yoshimura A, Shudo N, Ikeda S, Ichikawa M, Sumizawa T, Akiyama S
Cancer Lett
. 1990 Apr;
50(1):45-51.
PMID: 1969768
P-glycoprotein (P-gp) is involved in the transport of a wide variety of organic compounds including a fluorescent dye, rhodamine 6G (RG), as well as anti-cancer drugs. Agents that overcome classical...
8.
Kamiwatari M, Nagata Y, Kikuchi H, Yoshimura A, Sumizawa T, Shudo N, et al.
Cancer Res
. 1989 Jun;
49(12):3190-5.
PMID: 2566378
Ten synthetic dihydropyridine analogues were investigated for their ability to reverse drug resistance in a multidrug-resistant human carcinoma cell line, KB-Cl. Four dihydropyridine analogues completely reversed the resistance, three lowered...
9.
Hosoya K, Shudo N, Sugibayashi K, Morimoto Y
Chem Pharm Bull (Tokyo)
. 1987 Feb;
35(2):726-33.
PMID: 3594683
No abstract available.